公开(公告)号：US20220226290A1

公开(公告)日：2022-07-21

申请号：US17596356

申请日：2020-04-30

Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBH ,  University of Georgia Research Foundation, Inc.

Inventor： Anne Michelle TRAAS ,  Amanda ERICKSON COLEMAN ,  Bianca Natália FERREIRA DE MOURA LOURENCO ,  Kate Elizabeth CREEVY ,  Scott Alan Brown

IPC: A61K31/4184 ,  A61P9/12 ,  A61K45/06

Abstract: The present invention relates to telmisartan or a pharmaceutically acceptable salt thereof as a medicament for the treatment of hypertension in dogs, wherein the therapeutically effective amount of telmisartan is administered in a daily dosage amount that is varied over a treatment period.

公开(公告)号：US20210106564A1

公开(公告)日：2021-04-15

申请号：US17131312

申请日：2020-12-22

Applicant: Boehringer Ingelheim Vetmedica GmbH

Inventor： Balazs ALBRECHT ,  Sven ANKE ,  Saskia KLEY ,  Stefan Johannes LEHNER ,  Marcus STARK ,  Anne Michelle TRAAS ,  Tanja Margrit ZIMMERING

IPC: A61K31/4178 ,  A61K9/00 ,  A61P9/12 ,  A61K31/4184

Abstract: A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, where the therapeutically effective amount of the sartan is administered in a daily dosage amount that is varied over a treatment period, the daily dosage amount of the sartan for a first period of time during the treatment period is 1.0 to 5.0 mg/kg of body weight, and the daily dosage amount of the sartan is decreased for a second period of time subsequent the first period of time during the treatment period.

公开(公告)号：US20220218671A1

公开(公告)日：2022-07-14

申请号：US17596351

申请日：2020-04-30

Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBH ,  University of Georgia Research Foundation, Inc.

Inventor： Anne Michelle TRAAS ,  Amanda ERICKSON COLEMAN ,  Bianca Natália FERREIRA DE MOURA LOURENCO ,  Kate Elizabeth CREEVY ,  Scott Alan Brown

IPC: A61K31/4184 ,  A61K45/06 ,  A61P13/12 ,  A61P9/12

Abstract: The present invention relates to telmisartan or a pharmaceutically acceptable salt thereof as a medicament for the treatment of elevated urinary protein-to-creatinine ratio (UPC) levels in dogs, wherein the therapeutically effective amount of telmisartan is administered in a daily dosage amount that is varied over a treatment period.

公开(公告)号：US20190008831A1

公开(公告)日：2019-01-10

申请号：US16027422

申请日：2018-07-05

Applicant: Boehringer Ingelheim Vetmedica GmbH

Inventor： Balazs ALBRECHT ,  Sven ANKE ,  Saskia KLEY ,  Stefan Johannes LEHNER ,  Marcus STARK ,  Anne Michelle TRAAS ,  Tanja Margrit ZIMMERING

IPC: A61K31/4178 ,  A61P9/12 ,  A61K9/00

Abstract: A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, where the therapeutically effective amount of the sartan is administered in a daily dosage amount that is varied over a treatment period, the daily dosage amount of the sartan for a first period of time during the treatment period is 1.0 to 5.0 mg/kg of body weight, and the daily dosage amount of the sartan is decreased for a second period of time subsequent the first period of time during the treatment period.